Development of a rapid phenotypic test for HCV protease inhibitors with potential use in clinical decisions

Approximately 185 million people worldwide are chronically infected with hepatitis C virus (HCV). The first-wave of approved NS3 protease inhibitors (PIs) were Telaprevir and Boceprevir, which are currently discontinued. Simeprevir is a second-wave PI incorporated into the Brazilian hepatitis C trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Pessoa, Luciana Santos, Vidal, Luãnna Liebscher, da Costa, Emmerson C.B., Abreu, Celina Monteiro, da Cunha, Rodrigo Delvecchio, Valadão, Ana Luiza Chaves, dos Santos, André Felipe, Tanuri, Amilcar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Genética 2016
Materias:
Special Series of Articles - 60 Years of The Brazilian Society of Genetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5004841/
https://www.ncbi.nlm.nih.gov/pubmed/27575432
http://dx.doi.org/10.1590/1678-4685-GMB-2016-0022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5004841/
https://www.ncbi.nlm.nih.gov/pubmed/27575432
http://dx.doi.org/10.1590/1678-4685-GMB-2016-0022

Ejemplares similares